Takeda Pharmaceutical Company Limited obtained European Patent EP3856185A1 for balipodect, a pharmaceutical compound classified under A61K 31/501, for use in treating or preventing autism spectrum disorders. The patent application was filed with inventors led by Mahindra Makhija and received A1 publication status. The designation covers all EU member states plus Switzerland, Turkey, and other extension countries, providing Takeda exclusive commercial rights across these jurisdictions.

Pharmaceutical companies and researchers developing competing autism therapies should note this patent placement as it may restrict freedom to operate in this therapeutic space. Generic manufacturers and biosimilar developers should conduct freedom-to-operate analyses before entering the European market with related compounds. IP professionals should update portfolio databases to reflect this new grant and monitor for potential challenges or related patent family members.